יחס חוב לטווח ארוך להון Tyra Corp (TYRA)
Tyra Biosciences, Inc. (TYRA) is developing cutting-edge treatments for cancer and bone pathologies that are currently in the trial stage. Capital stability is supported by a robust balance sheet and patent protection, while future cash flow is tied to clinical results. The innovative approach is based on IT-driven molecular modeling to combat tumors. This price chart, where the indicator stands at 0.01, visualizes the dynamics of this high-tech business.
פילוחים אנליטיים של חברת Tyra Biosciences, Inc.
The stability of Tyra Biosciences, Inc. (TYRA) is determined by the balance between borrowed funds and equity, where the share of long-term liabilities in capital reflects the business's degree of financial autonomy. Low dependence on creditors is critical for Tyra Biosciences, Inc. (TYRA), as it allows the company to allocate resources toward AI modeling and the robotization of drug screening without the risk of forced liquidation due to debt burden.